

## ANSWERING REVIEWERS

August 24, 2015

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: Maiese-WJD-EPO(F-2)(Rev).doc)

**Title:** Erythropoietin and Diabetes Mellitus

**Author:** Kenneth Maiese

**Name of Journal:** *World Journal of Diabetes*

**ESPS Manuscript NO:** 20577

We are grateful to the reviewers for their comments. The manuscript was considered to be well written, well organized, was up-to-date, related and relevant to diabetes, comprehensive, and helpful. We have addressed reviewer suggestions as follows:

Reviewer 1:

1. As suggested, we have covered both the protective and non-protective aspects of EPO during diabetes mellitus.
2. As suggested, we have added additional discussion in the "Conclusions" section to discuss multiple future possibilities for EPO that involve modifying the structure of EPO, EPO mimetics, and use of the down-stream pathways of EPO.

Reviewer 2:

1. As suggested, we discussed the relevance of EPO in diabetes mellitus and in regards to the signal transduction pathways of EPO.
2. As suggested, we discussed the signal transduction pathways of EPO and included those of oxidative stress.
3. As suggested, we discussed the adverse effects of EPO.
4. As suggested, we have added additional discussion in the "Conclusions" section to discuss multiple future possibilities for EPO that involve modifying the structure of EPO, EPO mimetics, and use of the down-stream pathways of EPO.
5. As suggested, we revised the figure to now have 2 new figures so that Figure 1 presents the signal transduction pathways of EPO and Figure 2 presents the beneficial outcomes of EPO with the adverse effects.



6. As suggested, we corrected all grammatical errors found.
7. As suggested, we clarified and corrected any writing not previously clear.

Reviewer 3:

1. As suggested, we clarified and corrected any writing not previously clear.
2. As suggested, we have added additional discussion in the "Conclusions" section to discuss multiple future possibilities for EPO that involve modifying the structure of EPO, EPO mimetics, and use of the down-stream pathways of EPO.
3. As suggested, we corrected all grammatical errors found.

Reviewer 4:

1. As suggested, diabetic complications relevant to EPO were discussed.
2. The pros and cons of using EPO for diabetes mellitus were presented and clinical studies with EPO were discussed.
3. As suggested, we have added additional discussion in the "Conclusions" section to discuss multiple future possibilities for EPO that involve modifying the structure of EPO, EPO mimetics, and use of the down-stream pathways of EPO.
4. As suggested, we have added additional discussion in the "Conclusions" section to discuss multiple future possibilities for EPO that involve modifying the structure of EPO, EPO mimetics, and use of the down-stream pathways of EPO.
5. As suggested, we corrected all grammatical errors found.
6. As suggested, we removed the requested sentence.

Thank you again for publishing our manuscript in the *World Journal of Diabetes*.

Sincerely yours,

*Kenneth Maiese*

Kenneth Maiese, MD

E-mail: wntin75@yahoo.com